Gene sequencing company Pacific Biosciences of California is seeking two new leaders in the wake of retirement announcements by a pair of longtime top executives.
PacBio (NASDAQ: PACB) president and CEO Michael Hunkapiller plans to retire by year’s end, and... Read more »
At some point, every biotech weighs whether to forge ahead alone or team up with a larger company that has the scientific know-how, clinical trial experience, or the cash to keep a program going. For early-stage developers of cell and gene... Read more »
The FDA on Monday approved a new drug for patients with advanced small cell lung cancer, permitting the treatment to be marketed based on less evidence than it traditionally requires in order to speed its path to market.
Madrid-based PharmaMar, which... Read more »
The newest attention deficit hyperactivity disorder (ADHD) treatment comes with instructions unlike any other therapy: Press “PLAY.”
Akili Interactive was awarded FDA clearance on Monday for EndeavorRx, a “digital therapeutic” developed to treat ADHD through a video game experience. The regulatory... Read more »
The FDA on Monday revoked its emergency authorization permitting use of the antimalarial drugs hydroxychloroquine and chloroquine to treat the novel coronavirus, citing a lack of evidence of their efficacy.
In late March the agency authorized the drugs, which President Donald... Read more »
Less than a month after reporting preliminary early-stage data for its experimental vaccine for the novel coronavirus, Moderna has finalized the plan for a Phase 3 test.
The study, set to begin next month, is targeting enrollment of about 30,000 volunteers,... Read more »
Verve Therapeutics aims to use gene editing to address heart attacks by targeting the liver, not the heart. And it wants to make its edits inside the patient. The startup’s approach raises a lot of questions. Verve has some answers now,... Read more »
Hearing loss can stem from a variety of reasons, but in rare cases it’s caused by genetic defects. Akouos is developing a gene therapy to address these problems and it’s planning an IPO to finance the first tests of its approach... Read more »
Race is not a topic that often comes up in pharmaceutical discussions but perhaps it should. Disease doesn’t discriminate by race, but health and economic disparities put some groups at higher risk than others. And yet clinical trials fail to reflect... Read more »